Abstract 1668P
Background
There is scant attention given to the distress experienced by cancer patients or their caregivers in low-middle income countries like India. This study measures patient and caregiver distress in oncology and attempts to evaluate any correlation between the two.
Methods
All cancer patients ≥18 years and their primary caregiver were invited to participate in a survey which included demographic, disease, and therapy details, the NCCN distress scale for the patient and the Zarit Burden Interview (Short 12 items) questionnaire for the caregiver. An open-ended interview was used to record any additional problems.
Results
250 patients and corresponding caregivers completed the survey. 70.4% patients and 32.4% caregivers had moderate to severe distress burden. The average distress score for the patients and caregiver was 4.82 and 17.88 on the respective scales. Higher mean distress scores were seen in patients younger than 40 years, those from a rural background, having secondary or higher education and those on active or palliative treatment. Distress in patients was independent of gender, income group and hospital admission. Commonest care givers were sons (38.8%) and husbands (25.6%). Daughters as caregivers had the highest mean average burden (22.6). When scored individually, the question on enough time for oneself (Q1) and stress towards other responsibilities (Q2) had the highest mean scores (1.9) while the lowest average score (0.9) was found for the question regarding strain felt around patient. Open ended interview identified financial stress and sexual frustration as common causes cause of caregiver distress. On generating a scatter plot using linear regression, a definite trend was seen of rising patient distress with an increase in caregiver distress and Pearson’s Chi square test revealed a statistically significant association with the patient and caregiver distress scores (p <.0001).
Conclusions
There is significant unaddressed distress in both cancer patients and caregivers with a definite association between them. Open ended interviews also gave insight into causes of distress. Distress screening, co- counselling and early psycho-oncological interventions may help address these lacunae.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
N. Bisht.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1617P - Multi-gene copy number variation risk-score for prediction of survival and therapy response outcome in treatment-naïve metastatic castrate resistant prostate cancer
Presenter: Manish Kohli
Session: Poster session 11
1618P - Clinical prognostic factors within the high volume subgroup of metastatic hormone sensitive prostate cancer (mHSPC) in ENZAMET (ANZUP 1304)
Presenter: Anis Hamid
Session: Poster session 11
1619P - Efficacy of carboplatin in patients with metastatic castration-resistant prostate cancer: Results from the biomarker-driven, randomised, outcome-adaptive ProBio trial
Presenter: Anna Kristiansen
Session: Poster session 11
1620P - Inherited variants in SRD5A genes and response to hormonal therapy in prostate cancer (SWOG S1216)
Presenter: Sue Ingles
Session: Poster session 11
Resources:
Abstract
1621P - Validation of a digital pathology-based multimodal artificial intelligence (MMAI) prostate biopsy biomarker in a prospective, real-world Swedish prostate cancer (PCa) cohort treated with radical prostatectomy
Presenter: Anders Bjartell
Session: Poster session 11
1622P - A phase II study of the first-in-class oral innate immune activator BXCL701 with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC): Long-term follow-up
Presenter: Rahul Aggarwal
Session: Poster session 11
1623P - Prognostic value of circulating tumour DNA fraction in metastatic castration-resistant prostate cancer: Insights from the ProBio trial
Presenter: Alessio Crippa
Session: Poster session 11
1624P - Total and regional changes in body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation + enzalutamide +/- zoledronic acid: The BonEnza study
Presenter: Martina Buffoni
Session: Poster session 11
1625P - Fuzuloparib combined with abiraterone in the neoadjuvant treatment of localised high-risk prostate cancer (FAST-PC): A single-arm phase II study
Presenter: Yao Zhu
Session: Poster session 11